- Home
- ACHV vs GAN Comparison
ACHV vs GAN Comparison
Compare ACHV & GAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHV
- GAN
- Stock Information
- Founded
- ACHV N/A
- GAN 1999
- Country
- ACHV Canada
- GAN United States
- Employees
- ACHV N/A
- GAN N/A
- Industry
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- GAN Computer Software: Programming Data Processing
- Sector
- ACHV Health Care
- GAN Technology
- Exchange
- ACHV Nasdaq
- GAN Nasdaq
- Market Cap
- ACHV 92.6M
- GAN 81.1M
- IPO Year
- ACHV N/A
- GAN 2020
- Fundamental
- Price
- ACHV $2.70
- GAN $1.77
- Analyst Decision
- ACHV Strong Buy
- GAN
- Analyst Count
- ACHV 4
- GAN 0
- Target Price
- ACHV $15.75
- GAN N/A
- AVG Volume (30 Days)
- ACHV 162.2K
- GAN 208.5K
- Earning Date
- ACHV 03-11-2025
- GAN 03-14-2025
- Dividend Yield
- ACHV N/A
- GAN N/A
- EPS Growth
- ACHV N/A
- GAN N/A
- EPS
- ACHV N/A
- GAN N/A
- Revenue
- ACHV N/A
- GAN $134,998,000.00
- Revenue This Year
- ACHV N/A
- GAN $19.57
- Revenue Next Year
- ACHV N/A
- GAN $6.85
- P/E Ratio
- ACHV N/A
- GAN N/A
- Revenue Growth
- ACHV N/A
- GAN 4.31
- 52 Week Low
- ACHV $2.51
- GAN $1.17
- 52 Week High
- ACHV $5.59
- GAN $1.90
- Technical
- Relative Strength Index (RSI)
- ACHV 41.28
- GAN 46.66
- Support Level
- ACHV $2.70
- GAN $1.76
- Resistance Level
- ACHV $2.99
- GAN $1.81
- Average True Range (ATR)
- ACHV 0.20
- GAN 0.03
- MACD
- ACHV 0.01
- GAN 0.00
- Stochastic Oscillator
- ACHV 34.55
- GAN 37.50
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About GAN GAN Limited
GAN Ltd provides Software-as-a-Service solutions for online casino gaming and sports betting applications. The company has two operating segments B2B and B2C. The B2B segment develops, markets, and sells instances of GameSTACK, GAN Sports, and iSight Back Office technology that incorporates comprehensive player registration, account funding, and back-office accounting and management tools that enable the casino operators to efficiently, confidently, and effectively extend their presence online in places that have permitted online real money gaming, and The B2C segment, which includes the operations of Coolbet, develops and operates a B2C online sports betting and casino platform that is accessible through its website in markets across Northern Europe, Latin America, and Canada.